Antiretroviral Therapy
You are just a few steps away from free CE credits!
1
Sign in or Register
A free account is required.
2
Study the Material
An entire Cc section, or just a few topics at a time.
3
Take the CE Quiz
5 questions covering the topics in each Cc section.
4
Claim CE Credit
Free CNE and Free CME available!
Section Navigation
Section Navigation
- Lesson 4 Overview
Switching or Simplifying Antiretroviral Therapy - 0%Topic 1
Principles of Switching or Simplifying Antiretroviral TherapyActivities - 0%Topic 2
Switching to an Integrase Strand Transfer InhibitorActivities - 0%Topic 3
Switching to a Non-Nucleoside Reverse Transcriptase InhibitorActivities - 0%Topic 4
Within-Class Nucleoside Reverse Transcriptase Inhibitor SwitchesActivities - 0%Topic 5
Simplifying Therapy to An Oral Two-Drug RegimenActivities - 0%Topic 6
Simplifying Therapy to Injectable Cabotegravir and RilpivirineActivities - 0%Topic 7
Simplifying Maintenance Therapy to MonotherapyActivities - 0%Topic 8
Summary PointsActivities - Switching or Simplifying Antiretroviral Therapy CE Quiz
Switching or Simplifying Antiretroviral Therapy Overview
About this Lesson
Last Updated: February 3rd, 2025
CNE/CME Continuing Education
This lesson qualifies for:
View CE Notices
- 1.5 CME AMA PRA Category 1 Credits™, or
- 1.5 CNE contact hours and 1.5 CE contact hours (qualifies for pharmacology CE for advanced practice nurses)
CNE and CME Origination: June 1st, 2017
CNE and CME Review: September 1st, 2023
CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE Notices
Steps to Acquire CE for this Lesson:
1
Quiz
Score 80%+
2
Give Feedback
Complete survey
3
Print CE Certificate
Obtain proof of CE3rd Edition
This is a substantial revision of the original Lesson. The previous edition was titled Switching or Simplifying Antiretroviral Therapy and available until September 1st, 2023.
Learning Objectives
- Discuss the rationale for switching or simplifying antiretroviral therapy
- Describe common situations to consider for simplifying antiretroviral therapy
- Explain why some antiretroviral medications generally warrant a switch to a newer agent
- List the two-drug regimens that have been FDA-approved for maintenance antiretroviral therapy
- Summarize key findings with studies involving a switch to an integrase strand transfer inhibitor
Lesson Contributors
Authors
Brian R. Wood, MD
Brian R. Wood, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Disclosures:
None
Reviewers
David H. Spach, MD
David H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Disclosures:
None
Lesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Question Bank
Interactive board-review style questions about Epidemiology of HIV.
CNE/CME CME+MOC credits and CNE contact hours available.